![](https://investorshub.advfn.com/uicon/642020.png?cb=1510658609)
Tuesday, December 12, 2017 3:41:15 PM
• The HeartSentry measures the function of the endothelium – the critical inner lining of a person’s cardiovascular system.
• The core research and IP portfolio has been exclusively licensed to the company.
• Lexington is in final stages of releasing the product into clinical studies for FDA approval.
• The cardiovascular diagnostic market is growing fast and evolving into
personalized medicine.
• The goal is to make HeartSentry the standard of care for cardiologists, general
practitioners, and ultimately patients first line evaluation of cardiovascular health.
• We seek the participation of dedicated stakeholders and committed
partners who share our vision of the future of cardiovascular personalized medicine.
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM